Alpha 2.0
Login Register
» Articles » PMID: 21318912

In Vitro Immunogenicity Risk Assessment of Therapeutic Proteins in Preclinical Setting

Overview
Journal Methods Mol Biol
Specialty Molecular Biology
Date 2011 Feb 15
PMID 21318912
Citations 9
Authors
Puneet Gaitonde
Sathy V Balu-Iyer
Affiliations
Soon will be listed here.
Abstract

Immunogenicity against therapeutic proteins is a clinical problem in the successful treatment of many diseases and, as such, immunogenicity risk assessment in preclinical setting would be useful to improve safety and efficacy of protein-based therapeutics in the product development stages. Here, we attempted a mechanism-based in vitro study as screening tool to capture clinically observed antibody-based immune response against two representative therapeutic proteins: recombinant human Erythropoietin-alpha (rHuEPO)and recombinant Factor VIII (rFVIII). Flow-cytometry was used to determine the maturation level of dendritic cells (DCs), a primary initiator of T-cell responses. Studies to capture T-lymphocyte proliferation upon challenge with free rFVIII were performed and secretion of immunomodulatory cytokines was analyzed by ELISA assay. These in vitro techniques could be used as risk assessment tool to determine the immunogenic potential of formulations of recombinant proteins in preclinical setting.

Citing Articles

Immune regulatory adjuvant approach to mitigate subcutaneous immunogenicity of monoclonal antibodies.

Jarvi N, Patel M, Shetty K, Nguyen N, Grasperge B, Mager D Front Immunol. 2024; 15():1496169.

PMID: 39720710 PMC: 11666448. DOI: 10.3389/fimmu.2024.1496169.

A High Threshold of Biotherapeutic Aggregate Numbers is Needed to Induce an Immunogenic Response In Vitro, In Vivo, and in the Clinic.

Cohen J, Brych S, Prabhu S, Bi V, Elbaradei A, Tokuda J Pharm Res. 2024; 41(4):651-672.

PMID: 38519817 DOI: 10.1007/s11095-024-03678-2.

Unraveling the Effect of Immunogenicity on the PK/PD, Efficacy, and Safety of Therapeutic Proteins.

Smith A, Manoli H, Jaw S, Frutoz K, Epstein A, Khawli L J Immunol Res. 2016; 2016:2342187.

PMID: 27579329 PMC: 4992793. DOI: 10.1155/2016/2342187.

Phosphatidylserine Converts Immunogenic Recombinant Human Acid Alpha-Glucosidase to a Tolerogenic Form in a Mouse Model of Pompe Disease.

Schneider J, Balu-Iyer S J Pharm Sci. 2016; 105(10):3097-3104.

PMID: 27488899 PMC: 5021602. DOI: 10.1016/j.xphs.2016.06.018.

Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational Modifications.

Kuriakose A, Chirmule N, Nair P J Immunol Res. 2016; 2016:1298473.

PMID: 27437405 PMC: 4942633. DOI: 10.1155/2016/1298473.

References
1.
Lutz M, Kukutsch N, OGILVIE A, Rossner S, Koch F, Romani N . An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods. 1999; 223(1):77-92. DOI: 10.1016/s0022-1759(98)00204-x. View
2.
Purohit V, Ramani K, Sarkar R, Kazazian Jr H, Balasubramanian S . Lower inhibitor development in hemophilia A mice following administration of recombinant factor VIII-O-phospho-L-serine complex. J Biol Chem. 2005; 280(18):17593-600. PMC: 2582172. DOI: 10.1074/jbc.M500163200. View
3.
Ramani K, Miclea R, Purohit V, Mager D, Straubinger R, Balu-Iyer S . Phosphatidylserine containing liposomes reduce immunogenicity of recombinant human factor VIII (rFVIII) in a murine model of hemophilia A. J Pharm Sci. 2007; 97(4):1386-98. PMC: 2574438. DOI: 10.1002/jps.21102. View
4.
Zheng S . The Critical Role of TGF-beta1 in the Development of Induced Foxp3+ Regulatory T Cells. Int J Clin Exp Med. 2008; 1(3):192-202. PMC: 2592590. View
5.
Hara M, Kingsley C, Niimi M, Read S, Turvey S, Bushell A . IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo. J Immunol. 2001; 166(6):3789-96. DOI: 10.4049/jimmunol.166.6.3789. View